Venous Diseases
Conference Coverage
Controversy surrounds calf vein thrombosis treatment
CHICAGO – Anticoagulation, filter, or surveillance? Large retrospective study provides answers.
Conference Coverage
Late thrombectomy for stroke has low number needed to treat for benefit
LOS ANGELES – The number needed to treat varied according to the level of functional outcome achieved.
News
New hematologic, cardiovascular system link may have therapeutic implications
Early research sheds light on sex differences in thrombosis risk.
Opinion
Use of non–vitamin K antagonist oral anticoagulants in the acute care, periprocedural settings
NOACs: Handle with care because only a few have a back door.
Conference Coverage
DAPT duration: How low can you go?
DENVER – For STEMI, 6 months was as good as 12 in “hypothesis-generating” RCT.
Conference Coverage
EVAR, venous CPT coding revamped for 2018
CHICAGO – Current Procedural Terminology coding for endovascular aneurysm repair has been totally overhauled for 2018 with the introduction of a...
Conference Coverage
Skin signs spotlight highest-risk SLE patients
GENEVA – “Those are the lupus patients who still die today.”
News
FDA approves first therapy treatment for EGPA
Approval of using mepolizumab for EGPA was based on data from a 52-week clinical trial that compared it with placebo, according to the FDA.
Conference Coverage
VTE rates in lenalidomide-treated NHL may warrant prophylaxis
ATLANTA – Lenalidomide as single agent had twice the VTE rate as lenalidomide with a biologic.
Conference Coverage
Edoxaban noninferior to dalteparin for cancer-associated VTE
ATLANTA – Twelve months of daily edoxaban was noninferior to subcutaneous therapy with dalteparin for VTE in patients with cancer.
